Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promise

Teva Pharmaceutical Industries stock jumped more than 6% early Wednesday after the company reported first-quarter sales that topped estimates and released positive late-stage trial data on a schizophrenia treatment.

Previous post Monster Beverage’s stock up 1.4% after company announces Dutch auction tender offer for up to $3 billion of its own stock
Next post U.S. prosecutors are examining whether Tesla committed securities or wire fraud in Autopilot probe: Reuters